Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3L7YG
|
|||
| Drug Name |
BIIB105
|
|||
| Synonyms |
ION541
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Amyotrophic lateral sclerosis [ICD-11: 8B60.0; ICD-9: 335.2] | Phase 2 | [1] | |
| Company |
Ionis; Biogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ataxin-2 messenger RNA (ATXN2 mRNA) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04494256) A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the ATXN2 Gene. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.